title: Management of Hodgkins Lymphoma: ICMR Consensus Document.
abstract: Pediatric Hodgkins lymphoma is a highly curable disease even in the developing world. Current treatment paradigms follow a risk and response based approach. The goal is to minimise treatment related short and long-term toxicity while maintaining excellent survival. A confirmed histopathological diagnosis and full staging work-up are essential prior to embarking on treatment and guidelines for these are provided in the text. All patients require combination chemotherapy while radiotherapy is usually reserved for a select subgroup depending on the protocol used. It is important to follow these patients for relapse in the first five years and life-long for late effects as most of them will be cured.
authors.affiliation: Department of Medical Oncology and Pediatric Oncology, Cancer Institute (W.I.A), Adyar, Chennai, India.
authors.forename: Venkatraman
authors.initials: V
authors.lastname: Radhakrishnan
authors.affiliation: Department of Pediatric Hematology & Oncology, Rajiv Gandhi Cancer Institute & Research Center, Rohini, Sector 5, Delhi, 110085, India. kapoor.gauri@gmail.com.
authors.forename: Gauri
authors.initials: G
authors.lastname: Kapoor
authors.affiliation: Department of Pediatric Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
authors.forename: Brijesh
authors.initials: B
authors.lastname: Arora
authors.affiliation: Pediatric Hematology Oncology Unit, Department of Pediatrics, Advanced Pediatric Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
authors.forename: Deepak
authors.initials: D
authors.lastname: Bansal
authors.affiliation: Department of Pediatric Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
authors.forename: Tushar
authors.initials: T
authors.lastname: Vora
authors.affiliation: Department of Pediatric Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
authors.forename: Maya
authors.initials: M
authors.lastname: Prasad
authors.affiliation: Department of Pediatric Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
authors.forename: Girish
authors.initials: G
authors.lastname: Chinnaswamy
authors.affiliation: Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
authors.forename: Siddharth
authors.initials: S
authors.lastname: Laskar
authors.affiliation: Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Sandeep
authors.initials: S
authors.lastname: Agarwala
authors.affiliation: NCD Division, Indian Council of Medical Research (ICMR), New Delhi, India.
authors.forename: Tanvir
authors.initials: T
authors.lastname: Kaur
authors.affiliation: Dr. B.R.A Institute-Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: G K
authors.initials: GK
authors.lastname: Rath
authors.affiliation: Department of Medical Oncology, Dr. B.R.A Institute-Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Sameer
authors.initials: S
authors.lastname: Bakhshi
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007194:India
chemical_list: D000970:Antineoplastic Agents
keywords: Chemotherapy; Hodgkins lymphoma; Radiotherapy